AtheroGenics, Inc.
Chronic inflammatory disease drug maker posts loss of $0.61 per share
Published in Pharma Investments, Ventures and Law Weekly, November 20th, 2005
Research and development expenses for the third quarter increased to $20.5 million, compared to $16.6 million for the comparable quarter in 2004. For the 9-month period ended September 30, 2005, research and development expenses increased to $56.0 million, compared to $44.5 million for the same period in 2004.
The increase in research and development spending in both periods resulted from higher clinical trial expenditures associated with the company's...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- Alpharma, Inc.
U.S., global generics business sold to Actavis for $810M - Anika Therapeutics, Inc.
Hyaluronic acid-based therapy developer reports 57% increase in revenues - Arena Pharmaceuticals, Inc.
Obesity drug developer records loss of $0.46 per share - Bio-Bridge Science
Vaccine maker listed on OTCBB - BioSyntech, Inc.
Agreement signed with Korean pharmaceutical company for purchase of 1.5M shares of stock - Bioniche Life Sciences, Inc.
Bladder cancer drug developer signs agreement for private financing - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
